Neurent Medical announced Cigna Healthcare intends to provide coverage for its Neuromark system for chronic rhinitis.
Cigna will provide coverage for Neuromark for treating the posterior nasal nerve by removing CPT 31242 posterior nasal nerve ablation using radiofrequency (RF) from its Experimental & Investigational (E&I) list, effective Sept. 15.
Related: Circa completes limited launch of transseptal access system
Galway, Ireland-based Neurent designed the system to optimize the treatment of posterior nasal nerves. It provides real-time feedback, guides proper electrode placement and confirms successful treatment delivery.
Neuromark features a flexible shaft and atraumatic leaflets that conform to the patient anatomy. This enables physicians to reach challenging areas in the nasal cavity while maximizing treatment coverage. The system delivers impedance-controlled, low-power radiofrequency (RF) energy to disrupt parasympathetic nerve signals. This addresses the key symptoms of chronic rhinitis, such as persistent nasal congestion and rhinorrhea (runny nose).
Neurent says the policy update helps improve patient access to treatment options for chronic rhinitis. It eliminates a barrier that previously limited the ability for ear, nose and throat (ET) physicians to treat Cigna patients using posterior nasal nerve ablation. The new policy supports more streamlined access to Neuromark for eligible patients, the company says.
“This is a significant moment for ENT providers and patients alike,” said Brian Shields, CEO of Neurent Medical. “Cigna’s reclassification of CPT 31242 reinforces the evolving understanding of chronic rhinitis and the role of targeted, minimally invasive interventions like NEUROMARK in managing the condition. We are committed to continue building on our large evidence base and working closely with the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) to support adoption across the US healthcare system”
